Last reviewed · How we verify
Investigational HIV vaccine dose A
Investigational HIV vaccine dose A is a Biologic drug developed by Institut Pasteur. It is currently in Phase 1 development.
At a glance
| Generic name | Investigational HIV vaccine dose A |
|---|---|
| Sponsor | Institut Pasteur |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Any Event in SOC
- Headache
- Pyrexia
- Injection site pain
- Fatigue
- Myalgia
- Upper respiratory tract infection
- Injection site swelling
- Pain
- Injection site erythema
- Gastrointestinal symptoms
- Irritability
Key clinical trials
- Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (PHASE1, PHASE2)
- Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults (PHASE3)
- Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (PHASE1)
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV (PHASE2)
- ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74 (PHASE1)
- Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa (EARLY_PHASE1)
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults (PHASE1)
- Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational HIV vaccine dose A CI brief — competitive landscape report
- Investigational HIV vaccine dose A updates RSS · CI watch RSS
- Institut Pasteur portfolio CI
Frequently asked questions about Investigational HIV vaccine dose A
What is Investigational HIV vaccine dose A?
Investigational HIV vaccine dose A is a Biologic drug developed by Institut Pasteur.
Who makes Investigational HIV vaccine dose A?
Investigational HIV vaccine dose A is developed by Institut Pasteur (see full Institut Pasteur pipeline at /company/institut-pasteur).
What development phase is Investigational HIV vaccine dose A in?
Investigational HIV vaccine dose A is in Phase 1.
What are the side effects of Investigational HIV vaccine dose A?
Common side effects of Investigational HIV vaccine dose A include Any Event in SOC, Headache, Pyrexia, Injection site pain, Fatigue, Myalgia.